Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type

[1]  S. Devries,et al.  Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. , 1994, The American journal of pathology.

[2]  O. Kallioniemi,et al.  Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. , 1997, The American journal of pathology.

[3]  G. Berx,et al.  E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. , 1996, Oncogene.

[4]  J. Foekens,et al.  c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. , 1992, Cancer research.

[5]  Fatteneh Ed. Tavassoli,et al.  Pathology of The Breast , 1992 .

[6]  J. Tischfield,et al.  High frequency in vivo loss of heterozygosity is primarily a consequence of mitotic recombination. , 1997, Cancer research.

[7]  A. Marchetti,et al.  mdm2 gene alterations and mdm2 protein expression in breast carcinomas , 1995, The Journal of pathology.

[8]  W. J. Brammar,et al.  Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. , 1987, Oncogene.

[9]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[10]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[11]  P. Devilee,et al.  At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer , 1994, Genes, chromosomes & cancer.

[12]  M. J. van de Vijver,et al.  © 1997 Cancer Research Campaign , 2022 .

[13]  E. Coene,et al.  Amplification units and translocation at chromosome 17q and c-erbB2 overexpression in the pathogenesis of breast cancer , 1998 .

[14]  F. O'Malley,et al.  Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. , 1997, The American journal of pathology.

[15]  J. Varley,et al.  Allelic imbalance in the region of the BRCA1 gene in ductal carcinoma in situ of the breast. , 1996, British Journal of Cancer.

[16]  P. Devilee,et al.  At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer , 1994, Genes, chromosomes & cancer.

[17]  D. Birnbaum,et al.  BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. , 1991, Oncogene.

[18]  E. Robecchi.  [Pathology of the breast]. , 1954, Minerva ginecologica.

[19]  M. J. Silverstein,et al.  Prognostic classification of breast ductal carcinoma-in-situ , 1995, The Lancet.

[20]  D. Pinkel,et al.  Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors , 2022 .

[21]  I. Andrulis,et al.  p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. , 1998, Cancer research.

[22]  J Piper,et al.  Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors , 1994, Genes, chromosomes & cancer.

[23]  P. Validire,et al.  Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. , 1994, Seminars in diagnostic pathology.

[24]  E. E. Gresch.  Genetic Alterations During Colorectal-Tumor Development , 1989 .

[25]  N. Nomura,et al.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor , 1986, Nature.

[26]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[27]  A. Sahin,et al.  Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. , 1995, Cancer research.

[28]  M. Vijver,et al.  E‐cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. , 1995, The EMBO journal.

[29]  M. J. van de Vijver,et al.  Ductal carcinoma in situ: a proposal for a new classification. , 1994, Seminars in diagnostic pathology.

[30]  S. Hirohashi,et al.  Point Mutation of the E–Cadherin Gene in Invasive Lobular Carcinoma of the Breast , 1994, Japanese journal of cancer research : Gann.

[31]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[32]  P. Seeburg,et al.  Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells , 1984, Nature.

[33]  E. Gabrielson,et al.  Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. , 1996, Cancer research.

[34]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.

[35]  J. Varley,et al.  Comparative genomic hybridisation of ductal carcinoma in situ of the breast: identification of regions of DNA amplification and deletion in common with invasive breast carcinoma , 1997, Oncogene.

[36]  N. Phillips,et al.  Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. , 1995, Cancer research.

[37]  Thea D. Tlsty,et al.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.

[38]  W. Gregory,et al.  The classification of ductal carcinoma in situ and its association with biological markers. , 1994, Seminars in diagnostic pathology.

[39]  M. Lagios,et al.  Ductal carcinoma in situ of the breast: reproducibility of histological subtype analysis. , 1997, Human pathology.

[40]  F. O'Malley,et al.  Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67. , 1997, Human pathology.

[41]  Y. Nakamura,et al.  Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespectively of differences in phenotype and extent of spread. , 1994, Cancer research.

[42]  F. Speleman,et al.  Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer , 1997, Virchows Archiv.

[43]  J. Varley,et al.  Mutation of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ. , 1996, British Journal of Cancer.

[44]  R. Brown,et al.  Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. , 1995, Journal of the National Cancer Institute.